[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

November 2020, Vol 6, No. 11, Pages 1662-1816

Original Investigation

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(11):1713-1721. doi:10.1001/jamaoncol.2020.3938

This cohort study evaluates the association of coffee consumption with disease progression and death in patients with advanced or metastatic colorectal cancer.

Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(11):1723-1730. doi:10.1001/jamaoncol.2020.4331

This prognostic study uses data from patients with outpatient medical or gynecologic oncology encounters to investigate the validity of a machine learning algorithm to predict patient 180-day mortality.

Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

Abstract Full Text
JAMA Oncol. 2020;6(11):1733-1740. doi:10.1001/jamaoncol.2020.3537

This cohort study uses data from an existing cohort of patients undergoing resection of pancreatic cancer to assess the overall survival of patients treated with neoadjuvant FOLFIRINOX after surgery for pancreatic ductal adenocarcinoma.

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

Abstract Full Text
has audio
JAMA Oncol. 2020;6(11):1741-1750. doi:10.1001/jamaoncol.2020.4232

This cohort study uses data from the National Cancer Database to assess the association between adjuvant chemotherapy and survival in patients with node-negative early-stage non–small cell lung cancer (NSCLC) with vs without high-risk pathologic features.

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(11):1751-1758. doi:10.1001/jamaoncol.2020.3927

This randomized clinical trial evaluates the efficacy and safety of nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer.

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2020;6(11):1759-1765. doi:10.1001/jamaoncol.2020.4338

This systematic review and meta-analysis assesses the association of the addition of daratumumab to backbone multiple myeloma regimens with progression-free survival among patients with cytogenetically defined high-risk multiple myeloma.

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(11):1766-1772. doi:10.1001/jamaoncol.2020.4515

This open-label phase 1 study assesses the antitumor activity, tolerability, and safety of dostarlimab for patients with recurrent or advanced deficient mismatch repair endometrial cancer that has progressed after platinum-containing chemotherapy.

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2020;6(11):e204429. doi:10.1001/jamaoncol.2020.4429

This randomized phase 2 clinical trial assesses the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in adult patients with non–small lung cancer.

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564

This randomized clinical trial assesses the efficacy of nivolumab plus ipilimumab in the treatment of patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.

Brief Report

Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer

Abstract Full Text
JAMA Oncol. 2020;6(11):1773-1777. doi:10.1001/jamaoncol.2020.3697

This cross-sectional survey study examines whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians, and if so, whether patient-level barriers are associated with racial differences.

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(11):1778-1782. doi:10.1001/jamaoncol.2020.3689

This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.

Research Letter

Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1805-1806. doi:10.1001/jamaoncol.2020.4408

This prospective observational study assesses changes in treatment plans for patients with lung cancer and qualifies the types of changes observed as a direct result of the coronavirus disease 2019 pandemic.

Early Detection of Human Papillomavirus–Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(11):1806-1808. doi:10.1001/jamaoncol.2020.4527

This case series examines HPV seropositivity and antibody levels in a cohort of older men who have sex with men.

Review

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(11):1793-1800. doi:10.1001/jamaoncol.2020.2832

This narrative review discusses the use of postoperative radiotherapy in men with prostate cancer.

JAMA Oncology Clinical Challenge

Watery Diarrhea in a Patient With Metastatic Appendiceal Adenocarcinoma

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(11):1801-1802. doi:10.1001/jamaoncol.2020.2178

A 72-year-old man with metastatic appendiceal adenocarcinoma undergoing chemotherapy with capecitabine plus oxaliplatin presents with lower abdominal pain and watery, large-volume diarrhea up to 15 times per day for the previous 3 weeks. What is your diagnosis?

Viewpoint

Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?

Abstract Full Text
JAMA Oncol. 2020;6(11):1693-1694. doi:10.1001/jamaoncol.2020.2404

This Viewpoint how the coronavirus disease 2019 pandemic can reshape care in patients with cancer to focus on discouraging unnecessary in-person visits, testing, and low-value treatments.

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(11):1694-1695. doi:10.1001/jamaoncol.2020.2493

This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.

Distancing Without Isolating—Connection in the Era of COVID-19

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1695-1697. doi:10.1001/jamaoncol.2020.2725

This Viewpoint highlights the problem of social isolation and distress experienced by patients with cancer during the era of COVID-19, as well as strategies for clinicians to support patients through the pandemic.

Telemedicine for Cancer Care in the Time of COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(11):1698-1699. doi:10.1001/jamaoncol.2020.2684

This Viewpoint discusses the loosening of Medicare & Medicaid restrictions regarding telemedicine during the coronavirus disease 2019 (COVID-19) pandemic.

Invited Commentary

Coffee and Colorectal Cancer: Is Improved Survival a “Perk of Coffee Drinking?

Abstract Full Text
JAMA Oncol. 2020;6(11):1721-1722. doi:10.1001/jamaoncol.2020.3313

Closing the Gap Between Machine Learning and Clinical Cancer Care—First Steps Into a Larger World

Abstract Full Text
JAMA Oncol. 2020;6(11):1731-1732. doi:10.1001/jamaoncol.2020.4314
Cancer Care Chronicles

Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has Taken

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1700-1701. doi:10.1001/jamaoncol.2020.2839

In this essay, an experienced oncologist mourns the loss of personal connection with patients and their families that has resulted from the social distancing of the COVID-19 era.

Poetry and Oncology

Walking the Gauntlet

Abstract Full Text
JAMA Oncol. 2020;6(11):1816. doi:10.1001/jamaoncol.2020.4346
Comment & Response

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection

Abstract Full Text
JAMA Oncol. 2020;6(11):1808-1809. doi:10.1001/jamaoncol.2020.3386

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection—Reply

Abstract Full Text
JAMA Oncol. 2020;6(11):1809-1810. doi:10.1001/jamaoncol.2020.3397

Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(11):1810. doi:10.1001/jamaoncol.2020.3389

Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(11):1810-1811. doi:10.1001/jamaoncol.2020.3400

The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting

Abstract Full Text
JAMA Oncol. 2020;6(11):1811-1812. doi:10.1001/jamaoncol.2020.3703

The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply

Abstract Full Text
JAMA Oncol. 2020;6(11):1812-1813. doi:10.1001/jamaoncol.2020.3706

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

Abstract Full Text
JAMA Oncol. 2020;6(11):1813. doi:10.1001/jamaoncol.2020.3946

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

Abstract Full Text
JAMA Oncol. 2020;6(11):1813-1814. doi:10.1001/jamaoncol.2020.3955

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge—Reply

Abstract Full Text
JAMA Oncol. 2020;6(11):1814-1815. doi:10.1001/jamaoncol.2020.3960
Correction

Error in Author Name

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1815. doi:10.1001/jamaoncol.2020.4696

Error in Coauthor’s Name

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1815. doi:10.1001/jamaoncol.2020.5133

Incorrect Supplement Version

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1815. doi:10.1001/jamaoncol.2020.5538
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(11):1662. doi:10.1001/jamaoncol.2019.4257
×